readthroughSign in
Oct 16, 2026People5 fact check notes

REGENXBIO board chair Mills resigns, Migausky named Chairman

Kenneth T. Mills will leave the REGENXBIO board effective October 21, 2026, and the company named George Migausky as the new Chairman.

REGENXBIO Inc. disclosed in an 8-K dated October 14, 2026 that Kenneth T. Mills resigned from the board of directors of REGENXBIO Inc. effective October 21, 2026.1

In connection with the departure, the Board appointed George Migausky as Chairman of the Board.1 The filing does not specify the effective date of Migausky's appointment.

The 8-K was signed on October 16, 2026 by Patrick J. Christmas II, Executive Vice President, Chief Strategy & Legal Officer, on behalf of REGENXBIO Inc.

Fact check notes

  • ImpreciseREGENXBIO board chair Mills resigns, Migausky named ChairmanThe filing never explicitly states that Kenneth T. Mills was the prior Chairman; it only reports his resignation from the board and the appointment of Migausky as the new Chairman 'in connection with' that departure. The headline's phrase 'board chair Mills resigns' asserts a title not explicitly confirmed by the source.
  • Checker's noteThe headline implies Mills was the prior board chair ('board chair Mills resigns'), but the filing never states this explicitly—only that he resigned as a director and Migausky was then named Chairman.
  • Sentence removedAccording to the filing, Mills recently became chief executive officer of another company and intends to focus his efforts on his new role.copied source wording
  • Sentence removedThe company stated that Mills' decision was not related to any disagreement with the Company on any matter relating to its operations, policies, or practices.copied source wording
  • Sentence removedThe filing also notes a related governance change: in accordance with the Company's Corporate Governance Guidelines, Daniel Tassé has stepped down from his position as Lead Independent Director, as the new Chairman is an independent director, but will remain a member of the Board.copied source wording

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.